Surgerii Robotics announced on LinkedIn that its Shurui single-port surgical robot garnered CE mark approval in Europe.
According to the company’s post, it marks the second-ever single-port robot approval in Europe. Surgical robotics leader Intuitive received CE mark for its da Vinci SP single-port robot in 2024. The company also says the system became the first single-port robot approved in Europe for pediatric surgery.
Related: Galvanize Therapeutics closes $100m Series C financing, hires new CEO
Beijing, China-based Surgerii says Shurui already has more than 2,000 successful surgeries under its belt. The company has collaborations with more than 70 hospitals in China and nearly 10 in Europe to date. It also partnered with IRCAD to establish a European Clinical Excellence Center to drive training, innovation and single-port demonstrations.
Surgerii touts the system’s “pioneering snake-like instruments” as potential game-changers in surgical robotics. It features multiple degrees of freedom, high-precision instruments, advanced motion-control algorithms and a surgeon-friendly interface.
The company says it empowers surgeons to perform complex procedures through just one tiny incision. This aims to minimize trauma and speed up recovery.
According to the company, the serpentine-arm, single-port laparoscopic robot has approval in China for use in laparoscopic lung surgery, urology, gynecology, general surgery and thoracic surgery.
“This achievement not only fills a global gap in single-port robotics but also highlights China’s strength in original medical innovation,” the company wrote. “Surgerii Robotics is now accelerating its global expansion to bring minimally invasive robotic surgery to more hospitals and patients worldwide.”
